Logo Logo Logo Logo Logo
  • HOME
  • ABOUT
    • Management
    • Board of Directors
  • ADDICTION
    • Alcohol Addiction
    • Limitations of Current AUD Therapies
    • Our Proposed Solution
  • TECHNOLOGY
    • Overview
    • Phase 2b Clinical Trial Results
    • History of Ondansetron Use for AUD
    • Strengths and Competitive Advantages
  • Newsroom
    • Press Releases
    • Media
  • INVESTORS
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • CONTACT
  • HOME
  • ABOUT
    • Management
    • Board of Directors
  • ADDICTION
    • Alcohol Addiction
    • Limitations of Current AUD Therapies
    • Our Proposed Solution
  • TECHNOLOGY
    • Overview
    • Phase 2b Clinical Trial Results
    • History of Ondansetron Use for AUD
    • Strengths and Competitive Advantages
  • INVESTORS
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • CONTACT

Press Releases

Investor Relations

Investor Relations

  • Overview
  • Analyst Coverage
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance

Adial Pharmaceuticals to Present at 23rd Annual ICR Conference

Jan 11, 2021

Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder

Jan 11, 2021

Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder

Dec 17, 2020

Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory

Dec 15, 2020

Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments

Dec 10, 2020

Adial Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment of Addiction

Dec 10, 2020

Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley

Dec 9, 2020

Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured in Follow-up TV News Story

Dec 4, 2020

Adial Pharmaceuticals Lead Drug Candidate AD04 for Treatment of Alcohol Use Disorder Featured on Multiple Television News Outlets

Nov 25, 2020

Adial Pharmaceuticals Enters into Common Stock Purchase Agreement with Keystone Capital Partners to Support Strategic Opportunities and Future Growth Initiatives

Nov 25, 2020
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

©Adial Pharmaceuticals 2021